• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Armata Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    4/2/25 4:05:15 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARMP alert in real time by email
    false 0000921114 0000921114 2025-04-02 2025-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): April 2, 2025

     

    ARMATA PHARMACEUTICALS, INC.

    (Exact name of Registrant as specified in its charter)

     

    Washington   001-37544   91-1549568
    (State or other jurisdiction
    of incorporation or organization)
      (Commission File Number)   (IRS Employer Identification No.)

     

    5005 McConnell Avenue
    Los Angeles, California
      90066
    (Address of principal executive offices)   (Zip Code)

     

    (310) 655-2928

    (Registrant’s Telephone number)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Common Stock   ARMP   NYSE American

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    Armata Pharmaceuticals, Inc. (“Armata” or the “Company”) has set June 12, 2025 as the date for its 2025 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting will be held at 8:30 a.m. (Pacific Time), at the Company’s principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066, or at such other time and location to be determined by the Company’s Board of Directors and set forth in the Company’s proxy statement for the Annual Meeting. Armata’s stockholders of record at the close of business on April 17, 2025, will be entitled to notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting.

     

    The deadline for receipt of stockholder proposals and director nominations submitted pursuant to Section 2.6 of Armata’s Amended and Restated Bylaws for consideration at the Annual Meeting is 5:00 p.m. (Eastern Time) on April 13, 2025 (the “Advance Notice Bylaws Provision Deadline”). Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata’s principal executive offices at Armata Pharmaceuticals, Inc., 5005 McConnell Avenue, Los Angeles, California 90066, by the Advance Notice Bylaws Provision Deadline, in order to be considered timely. Stockholder proposals and nominations submitted pursuant to Armata’s advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata’s Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete text of such advance notice provisions.

     

    -2-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 2, 2025 Armata Pharmaceuticals, Inc.
       
      By: /s/ David House
      Name: David House
      Title:

    Senior Vice President, Finance and Principal Financial Officer 

     

    -3-

     

    Get the next $ARMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARMP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARMP
    Leadership Updates

    Live Leadership Updates

    See more
    • Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

      LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller. "We are delighted to welcome David to the Armata t

      8/15/24 4:45:00 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

      LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2023, and provided a corporate update.   Second Quarter 2023 and Recent Developments: Announced leadership transition whereby world‐renowned healthcare leader and former Innoviva Board member Dr. Deborah L. Birx has been appointed Armata's new Chi

      8/14/23 7:00:00 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

      Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t

      7/11/23 8:00:00 AM ET
      $ARMP
      $INVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ARMP
    SEC Filings

    See more
    • Armata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

      5/19/25 7:06:04 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Armata Pharmaceuticals Inc.

      10-Q - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

      5/14/25 4:23:23 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Armata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

      5/14/25 4:13:33 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Armata Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Armata Pharmaceuticals with a rating of Buy and set a new price target of $7.00 from $5.00 previously

      3/22/21 6:28:33 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

      All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES, May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Ph

      5/19/25 7:00:00 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

      LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 and Recent Developments: Anticipating announcement of topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 as

      5/14/25 4:05:00 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

      Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial LOS ANGELES, May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $4.65 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, recei

      5/1/25 7:00:00 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Birx Deborah covered exercise/tax liability with 28,986 shares, decreasing direct ownership by 11% to 231,014 units (SEC Form 4)

      4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

      4/25/25 4:07:12 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Business Officer Kyme Pierre covered exercise/tax liability with 1,027 shares, decreasing direct ownership by 9% to 10,491 units (SEC Form 4)

      4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

      4/25/25 4:06:15 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Kyme Pierre claimed ownership of 1,518 shares (SEC Form 3)

      3/A - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

      4/25/25 4:05:16 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARMP
    Financials

    Live finance-specific insights

    See more
    • Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

      Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023 Repurchased $11.0 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select cor

      11/1/23 4:15:00 PM ET
      $ARMP
      $INVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

      Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Repurchased $9.2 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives

      8/2/23 4:05:00 PM ET
      $ARMP
      $INVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Innoviva Reports First Quarter 2022 Financial Results

      Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue

      4/27/22 5:11:00 PM ET
      $ARMP
      $ETTX
      $INVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations